What is HHC?
HHC was first created in 1944 by American chemist Roger Adams when he added hydrogen molecules to Delta-9 THC.
This process, known as hydrogenation, converts THC into hexahydrocannabinol (HHC).
Hydrogenation is not limited to the production of cannabinoids. A similar process is used to turn vegetable oil into margarine.
While Adams created HHC from conventional THC derived from cannabis, today the cannabinoid is typically derived through a process that begins with hemp, the low-THC cannabis plant that Congress federally legalized in the 2018 farm bill.
As the name suggests (hexahydrocannabinol vs. tetrahydrocannabinol), HHC has many similarities to THC.
It is basically a stripped-down version of Delta 9 THC.
Both HHC and THC have very similar molecular structures and comparable effects.
It was discovered during research in the 1960s and 70s in which the goal was to find the most basic cannabinoid-like substances that could still bind to CB receptors.
One study in particular examined the angiogenic effects of various hexahydrocannabinol analogs to see how they might be used in cancer therapies.
According to the study: “Two analogs LYR-7 [(9S)-3,6,6,9-tetramethyl-6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromen-1-ol ] and LYR -8 [(1 – ((9S) -1-hydroxy-6,6,9-trimethyl-6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromen-2- il) ethanone )] were selected based on their antiangiogenic activity and lack of binding affinity for cannabinoid receptors.
Both LYR-7 and LYR-8 inhibited VEGF-induced proliferation, migration, and capillary formation of HUVEC in a concentration-dependent manner.”
“The inhibitory effect of the compounds on cell proliferation was more selective in endothelial cells than in breast cancer cells (MCF-7 and MCF-7 resistant to tamoxifen).
We also noted effective inhibition of VEGF-induced new blood vessel formation by the compounds in the chicken chorioallantoic membrane (CAM) assay in vivo.
Furthermore, both LYR analogs potently inhibited VEGF production and NF-κB transcriptional activity in cancer cells.”
“Furthermore, LYR-7 or LYR-8 strongly inhibited breast cancer cell-induced angiogenesis and tumor growth.
Taken together, these results suggest that the novel synthetic hexahydrocannabinol analogs, LYR-7 and LYR-8, inhibit tumor growth by targeting VEGF-mediated angiogenesis signaling in endothelial cells and suppressing VEGF production and growth of endothelial cells. cancer cells.”
Simply put, these compounds block the growth of blood vessels that feed tumors, rather than blocking the growth of the tumor itself.
So basically it works as an angiogenesis inhibitor that starves any tumor.